Indoco Remedies Ltd
INDOCOIndoco Remedies Ltd
INDOCO
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 40.91 | 2.83 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.79 | 6.62 | 0.48% |
Forecast & Ratings
Detailed Forecast from 4 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Indoco Remedies Limited is engaged in the manufacture of pharmaceutical products. The Company primarily manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,009.68 | 1,078.73 | 1,046.63 | 974.60 | 1,109.02 | 1,244.65 | 1,543.08 | 1,670.95 | 1,846.87 | 1,852.48 | ||||||||||
Raw Materials | 361.13 | 362.83 | 344.53 | 306.93 | 338.48 | 366.23 | 483.09 | 514.74 | 600.67 | 1,599.57 | ||||||||||
| Power & Fuel Cost | 21.72 | 23.12 | 26.62 | 28.49 | 34.75 | 36.89 | 42.78 | 50.61 | 56.00 | |||||||||||
| Employee Cost | 181.87 | 216.67 | 220.91 | 231.66 | 256.51 | 274.02 | 296.28 | 322.58 | 361.93 | |||||||||||
| Selling & Administrative Expenses | 216.81 | 255.89 | 246.31 | 241.21 | 287.26 | 257.82 | 292.67 | 339.43 | 414.96 | |||||||||||
| Operating & Other expenses | 56.18 | 59.79 | 68.64 | 83.51 | 66.38 | 82.30 | 98.59 | 155.15 | 147.62 | |||||||||||
EBITDA | 171.97 | 160.43 | 139.62 | 82.80 | 125.64 | 227.39 | 329.67 | 288.44 | 265.69 | 252.91 | ||||||||||
| Depreciation/Amortization | 60.66 | 63.28 | 67.71 | 71.57 | 70.82 | 73.13 | 78.96 | 70.61 | 91.87 | 99.51 | ||||||||||
| PBIT | 111.31 | 97.15 | 71.91 | 11.23 | 54.82 | 154.26 | 250.71 | 217.83 | 173.82 | 153.40 | ||||||||||
| Interest & Other Items | 12.39 | 6.21 | 23.51 | 20.54 | 26.25 | 22.26 | 14.14 | 25.03 | 38.02 | 44.54 | ||||||||||
| PBT | 98.92 | 90.94 | 48.40 | -9.31 | 28.57 | 132.00 | 236.57 | 192.80 | 135.80 | 108.86 | ||||||||||
| Taxes & Other Items | 16.99 | 13.87 | 7.23 | -6.41 | 4.46 | 38.95 | 81.77 | 50.55 | 37.33 | 32.16 | ||||||||||
| Net Income | 81.93 | 77.07 | 41.17 | -2.90 | 24.11 | 93.05 | 154.80 | 142.25 | 98.47 | 76.70 | ||||||||||
| EPS | 8.89 | 8.36 | 4.47 | -0.31 | 2.62 | 10.10 | 16.80 | 15.44 | 10.68 | 8.32 | ||||||||||
| DPS | 1.60 | 1.60 | 1.00 | 0.30 | 0.30 | 1.50 | 2.25 | 2.25 | — | 2.25 | ||||||||||
| Payout ratio | 0.18 | 0.19 | 0.22 | — | 0.11 | 0.15 | 0.13 | 0.15 | 0.00 | 0.27 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Indoco Remedies Ltd | 31.87 | 2.83 | — |
| Sun Pharmaceutical Industries Ltd | 47.30 | 6.75 | 0.72% |
| Cipla Ltd | 31.72 | 4.88 | 0.80% |
| Torrent Pharmaceuticals Ltd | 70.36 | 17.00 | 0.81% |
Price Comparison
Compare INDOCO with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Indoco Remedies Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 4.8807% | Percentage of the fund’s portfolio invested in the stock 0.57% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 78/110 (-10) |
Nippon India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.1900% | Percentage of the fund’s portfolio invested in the stock 0.16% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 149/238 (-42) |
DSP Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.7615% | Percentage of the fund’s portfolio invested in the stock 2.75% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/33 (0) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2024
Dividend/Share
₹1.50
Ex DateEx Date
Sep 19, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹2.25
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 14, 2022
Dividend/Share
₹0.75
Ex DateEx Date
Sep 14, 2022
Cash Dividend
Ex DateEx DateSep 14, 2022
Dividend/Share
₹1.50
Ex DateEx Date
Sep 14, 2022
Cash Dividend
Ex DateEx DateSep 17, 2021
Dividend/Share
₹1.50
Ex DateEx Date
Sep 17, 2021
Indoco Remedies (Indoco) announced the receipt of final approval from the USFDA for Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets USP, 10 mg (OTC), a generic equivalent of the Reference Listed Drug, Zyrtec Allergy Tablets, 10 mg of Johnson & Johnson Consumer Inc. Cetirizine Hydrochloride Tablets USP, 10 mg will be manufactured by Indoco, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa - 403722 in India. Cetirizine is used for relief of symptoms of hay fever and other allergic conditions.Powered by Capital Market - Live
Indoco Remedies announced that the Annual General Meeting (AGM) of the company will be held on 26 September 2024.Powered by Capital Market - Live
Indoco Remedies has fixed 19 September 2024 as record date for determining entitlement of members to final dividend for the financial year ended 31 March 2024.Powered by Capital Market - Live
Stock that will see action today: July 29, 2024
Indoco Remedies consolidated net profit declines 89.26% in the June 2024 quarter
Net profit of Indoco Remedies declined 89.26% to Rs 2.62 crore in the quarter ended June 2024 as against Rs 24.39 crore during the previous quarter ended June 2023. Sales rose 1.79% to Rs 424.29 crore in the quarter ended June 2024 as against Rs 416.81 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales424.29416.81 2 OPM %11.2614.68 - PBDT34.4953.79 -36 PBT6.9733.91 -79 NP2.6224.39 -89 Powered by Capital Market - Live
Stock Alert: Reliance Industries, Cyient DLM, Zensar Tech, Suzlon Energy, Federal Bank, Gensol Engineering
Indoco Remedies - U.S. To Drive Growth: Nirmal Bang
USFDA Approves Indoco Remedies’ Generic Diabetes Drug
Indoco Remedies - Resolution Of Facilities A Key Monitorable: Nirmal Bang
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 13.64%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.44% to 0.49%